CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (Amex: JAV - News) today reported its unaudited financial results for the second quarter ended June 30, 2007.
Stephen J. Tulipano, Javelin's Chief Financial Officer, stated, "We were pleased to attract a number of new institutional investors in our follow-on offering in May and to achieve many clinical and operational milestones during the quarter. We continue to ramp up our commercialization efforts in anticipation of and are increasing our investment in an infrastructure that will support a potential product launch initially in Europe. Commensurate with preparation for these activities, our cash outflows are expected to significantly increase over the next twelve to eighteen months."
